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ORIGINAL

ARTICLE

Clinical and pathologic correlation of
cutaneous COVID-19 vaccine reactions
including V-REPP: A registry-based study
Devon E. McMahon, MD,a Carrie L. Kovarik, MD,b William Damsky, MD, PhD,c Misha Rosenbach, MD,b
Jules B. Lipoff, MD,b Anisha Tyagi, BA,d Grace Chamberlin, BA,d Ramie Fathy, AB,b
Rosalynn M. Nazarian, MD,e Seemal R. Desai, MD,f,g Henry W. Lim, MD,h Bruce H. Thiers, MD,i
George J. Hruza, MD, MBA,j Lars E. French, MD,k,l Kimberly Blumenthal, MD, MSc,m
Lindy P. Fox, MD,n and Esther E. Freeman, MD, PhDa,d
Boston, Massachusetts; Philadelphia, Pennsylvania; New Haven, Connecticut; Dallas and Plano, Texas;
Detroit, Michigan; Charleston, South Carolina; St. Louis, Missouri; Munich, Germany; Miami, Florida;
and San Francisco, California
Background: Cutaneous reactions after COVID-19 vaccination have been commonly reported; however,
histopathologic features and clinical correlations have not been well characterized.
Methods: We evaluated for a history of skin biopsy all reports of reactions associated with COVID-19
vaccination identified in an international registry. When histopathology reports were available, we
categorized them by reaction patterns.
Results: Of 803 vaccine reactions reported, 58 (7%) cases had biopsy reports available for review. The
most common histopathologic reaction pattern was spongiotic dermatitis, which clinically ranged from
robust papules with overlying crust, to pityriasis rosea-like eruptions, to pink papules with fine scale. We
propose the acronym ‘‘V-REPP’’ (vaccine-related eruption of papules and plaques) for this spectrum. Other
clinical patterns included bullous pemphigoid-like (n = 12), dermal hypersensitivity (n = 4), herpes zoster
(n = 4), lichen planus-like (n = 4), pernio (n = 3), urticarial (n = 2), neutrophilic dermatosis (n = 2),
leukocytoclastic vasculitis (n = 2), morbilliform (n = 2), delayed large local reactions (n = 2),
erythromelalgia (n = 1), and other (n = 5).
Limitations: Cases in which histopathology was available represented a minority of registry entries.
Analysis of registry data cannot measure incidence.
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Conclusion: Clinical and histopathologic correlation allowed for categorization of cutaneous reactions to
the COVID-19 vaccine. We propose defining a subset of vaccine-related eruption of papules and plaques,
as well as 12 other patterns, following COVID-19 vaccination. ( J Am Acad Dermatol https://doi.org/
10.1016/j.jaad.2021.09.002.)
Key words: Ad26.COV2.S; AZD1222; BNT162b2; bullous pemphigoid; chilblains; COVID-19; delayed large
local; dermal hypersensitivity reaction; dermatology; dermatopathology; erythema multiforme; erythromelalgia; Johnson & Johnson Janssen; lichen planus; Moderna; morbilliform; mRNA-1273; OxfordAstraZeneca; papular; papulosquamous; pathology; pernio; Pfizer-BioNTech; pityriasis rosea; psoriasis;
registry; SARS-CoV-2; Stevens-Johnson syndrome; urticaria; vaccine; zoster.

INTRODUCTION

METHODS

CAPSULE SUMMARY
As of June 2021, a total of
In December 2020, our
1.84 billion doses of COVIDinternational
COVID-19
19 vaccines have been
dermatology
registry,
estabIn this registry-based study, we observed
administered globally.1 The
lished
in
collaboration
with
diverse COVID-19 vaccine-associated
the
American
Academy
of
Moderna (mRNA-1273) and
cutaneous reactions, including
Dermatology
and
the
Pfizer-BioNTech (BNT162b2)
papulovesicular, pityriasis rosea-like, and
International
League
of
vaccines, which use a novel
papulosquamous eruptions classified as
Dermatological
Societies,
mRNA technology, have
vaccine-related eruption of papules and
began collecting reports of
been reported to cause
plaques.
patients with cutaneous
various dermatologic side efThis detailed study using the clinical and
reactions
to
COVID-19
fects, such as delayed large
histopathologic correlation of 13
vaccination (www.aad.org/
local reactions, local injection
reaction patterns may aid with the
covidregistry).2,7 Entry of desite reactions, urticaria, mordiagnosis of cutaneous side effects from
billiform reactions, erythroidentified patient cases was
the COVID-19 vaccine.
melalgia, zoster, pernio, and
restricted to only health care
cosmetic filler reactions.2-4
workers. The Massachusetts
General Brigham Institutional
The Johnson and Johnson
Review Board exempted this study as not human
(Ad26.COV2.S) vaccine, which uses a nonreplicating
subject research.
viral vector, appears to have relatively fewer dermaThe registry collected data regarding COVID-19
tologic side effects, with the clinical trial reporting
vaccination and characteristics of the cutaneous
only local injection site reactions.5 The Oxfordreactions.2 As in prior work, we defined a wheal on
AstraZeneca (AZD1222) trial reported local injection
site reactions and 1 case each of psoriasis, rosacea,
the vaccinated arm as a local injection site reaction if
vitiligo, and Raynaud’s syndrome, although realit occurred within 3 days of the first dose of
world studies are lacking.4,6
vaccination and a delayed large local reaction if it
occurred more than 4 days after vaccination.2
Although clinicopathologic correlation is key to
understanding the pathophysiology, to our knowlAdditionally, the registry queried whether a skin
edge there have been no systematic studies exambiopsy report was available and asked for full details
ining the clinicopathologic correlations between the
of any biopsy reports. Physicians and other health
cutaneous reactions associated with COVID-19 vaccare providers who entered pending or incomplete
cine across a broad spectrum of reaction patterns and
biopsy reports were contacted for updates and
their accompanying histopathology. Hence, the puradditional clarifying information. For records where
pose of this study was to improve the characterizafull biopsy reports were available, health care protion of dermatologic reactions to COVID-19
viders were then contacted to request de-identified
vaccination through an analysis of biopsy reports
patient photos.
and corresponding clinical photographs from cases
Biopsy reports, and clinical photographs when
entered into an international COVID-19 dermatology
available, were reviewed by 4 board-certified dermaregistry. Given that a growing percentage of the
tologists (Drs Kovarik, Damsky, Fox, and Freeman), 2
world’s population is being vaccinated, such data
of whom are dermatopathologists (Drs Kovarik and
may aid with the diagnosis of cutaneous side effects
Damsky); these were organized by group reaction
of COVID-19 vaccination.
patterns and histopathologic findings into
d

d
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Abbreviations used:
IQR:
interquartile range
V-REPP: vaccine-related eruption of papules and
plaques

harmonized clinical and histopathologic entities. We
used Stata (version 16, StataCorp LLC) to analyze data.

RESULTS
From December 24, 2020 to May 19, 2021, health
care providers entered 803 cases of COVID-19
vaccine-related cutaneous reactions into the
American
Academy
of
Dermatology
or
International League of Dermatological Societies
registry. A portion of these cases (n = 414) have
been previously reported without pathology.2 Of the
803 cases, vaccine manufacturers overall were
Moderna (69%), Pfizer (25%), Johnson and Johnson
(1.0%), Oxford-AstraZeneca (0.6%), and unspecified
(4.4%). The most commonly reported morphologies
were local injection site reactions, delayed large local
reactions, urticaria, morbilliform, zoster, and papulosquamous eruptions (Supplemental Table I; available via Mendeley at https://data.mendeley.com/
datasets/cyxcbmc5zc/1.) Cases were reported by
dermatologists (46%), other physicians (22%), midlevel providers (9.2%), nurses (9.1%), and other
health care providers (13%).
Of the 803 cases, 78 providers (9.7%) indicated
that a skin biopsy was performed. Records listed as
pending (n = 15) or incomplete (n = 5) were not
included, leaving 58 (7%) complete biopsy reports
for review (Table I). The median age of these 58
patients was 61 years (interquartile range [IQR], 4477); 62% were women, 75% were White, and 95%
were from the United States. The majority of cases for
whom skin biopsy reports were available were
reported by dermatologists (94%). Vaccine manufacturers were Moderna (46%), Pfizer (42%), Johnson
and Johnson (1.7%), Oxford/AstraZeneca (1.7%),
and unspecified (8.6%).
For patients receiving vaccines requiring 2 doses
(ie, primarily Moderna/Pfizer), 55% of biopsy reports
were taken following the first dose. Of note, 8 patients
biopsied after the first dose were not planning to
receive the second dose, given the severity of the
cutaneous reaction. These included 2 cases of leukocytoclastic vasculitis, 2 cases of papulosquamous
eruptions, 1 case of urticaria, 1 case of dermal
hypersensitivity reaction, 1 case of bullous pemphigoid, and 1 case of Stevens-Johnson syndrome.
Clinicopathologic correlation revealed 13
different COVID-19 vaccine reaction patterns where

McMahon et al 3

biopsy reports were evaluable: vaccine-related eruption of papules and plaques (V-REPP) (n = 15),
bullous pemphigoid-like (n = 12), dermal hypersensitivity reactions (n = 4), herpes zoster (n = 4), lichen
planus-like (n = 4), pernio (n = 3), urticaria (n = 2),
neutrophilic dermatosis (n = 2), leukocytoclastic
vasculitis (n = 2), morbilliform (n = 2), delayed large
local reactions (n = 2), erythromelalgia (n = 1), and
other (n = 5), including Stevens-Johnson syndrome
(n = 1) and erythema multiforme (n = 1). Clinical
photographs correlated with histopathology are
shown in Supplemental Fig 1 (available via
Mendeley at https://data.mendeley.com/datasets/
cyxcbmc5zc/1.)
The histologic reaction pattern most commonly
biopsied was a spectrum of spongiotic dermatitis
after Moderna (40%), Pfizer (47%), OxfordAstraZeneca (6.7%), and unspecified (6.7%) vaccines. These vaccine-related eruptions of papules
and plaques, which we call V-REPP (Fig 1), clinically
had papules and/or plaques with surface changes.
They ranged on a clinical spectrum from edematous
and crusted papules (robust), to edematous and
erythematous scaly papules and plaques resembling
pityriasis rosea-like changes (moderate), to subtle
scaly papules and plaques (mild). The findings were
clinically diverse, but had similar histopathology,
which existed on a spectrum related to the degree of
spongiosis present on the biopsy compared to the
degree of interface changes. Robust V-REPP on
biopsy showed marked spongiosis with intraepidermal vesicles and minimal to no interface changes
(biopsy reports, n = 3). Moderate V-REPP showed
moderate spongiosis more often than interface
changes (n = 8). Mild V-REPP demonstrated mild
spongiosis and more-prominent interface changes
(n = 4). Eosinophils were commonly present in the
cases with marked spongiosis and were less likely to
be present in the cases with minimal spongiosis.
The median time to V-REPP was 12 (IQR, 4-16)
days after COVID-19 vaccination. Robust V-REPP
occurred at a median of 5.5 (IQR, 4-7) days after
vaccination and lasted up to 49 days at the time of
reporting. However, because 100% of these eruptions were ongoing at the time of reporting, the
natural history of the cutaneous reaction has yet to be
determined. Moderate V-REPP occurred a median of
13 (IQR, 4-19) days after vaccination and lasted up to
90 days, with 88% ongoing at the time of reporting.
For several of the cases that were pityriasis rosealike, V-REPP started after the first dose of the mRNA
vaccine and then flared with the second dose. Mild
V-REPP occurred a median of 16 (IQR, 14-18) days
after vaccination and lasted up to 18 days, with 50%
ongoing at the time of reporting.
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V-REPP (n = 15)
Robust
Papulovesicular (n = 3)

Vaccine brand (%)

Distribution

Morphology (based on clinical
photograph review)

Histopathology

29-81

Moderna (33%), Pfizer (67%) Trunk, extremities [ neck,
face, head

Moderate Pityriasis rosea-like (n = 8)

41-82

Moderna (38%), Pfizer (50%), Trunk, extremities [ face
Oxford-AstraZeneca (12%)

Mild

31-71

Moderna (50%), Pfizer (25%), Trunk, extremities
Unspecified (25%)

42-97

Moderna (36%), Pfizer (64%) Trunk, extremities [ face,
head, neck, oral mucosa,
genital mucosa

Tense unilocular clear fluidfilled bullae on an
erythematous base

Subepidermal blister
formation and mixed
inflammation with
eosinophils
d C3d: 0/1 positive
d DIF: 5/8 positive for linear
IgG and C3 BMZ, 1/8 positive for only IgG BMZ
d ELISA: 1/1 positive BP180

34-83

Moderna (25%), Pfizer (25%), Trunk, extremities [ face,
Unspecified (25%)
neck

Pink edematous papules
coalescing into plaques
without surface change;
individual lesions last
[24 h

Perivascular infiltrate with
mixed inflammation,
which may include
lymphocytes, neutrophils,
and eosinophils

Papulosquamous with
subtle scale (n = 4)

Spongiotic dermatitis as
robust intercellular edema
with intraepidermal
vesicles, papillary dermal
edema, and dermal
eosinophils; interface
changes may or may not
be present
Spongiotic
Oval, pityriasis rosea-like
dermatitis [[ interface
pink edematous papules
changes and dermal
and plaques, some with
eosinophils are often
central crust and some
present
with trailing scale
Spongiosis as mild
Oval or annular pink thin
intercellular edema and
papules coalescing into
vacuolar interface
plaques, with mild surface
changes are present and
changes and subtle scale
may be focal; eosinophils
may or may not be
present
Discrete edematous
papules, some with
central vesiculation and
crusting

Bullous pemphigoid-like (n = 12)

Dermal hypersensitivity reaction (n = 4)

n 2021
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Table I. Categorization of clinical and histopathologic features of COVID-19 vaccine cutaneous reactions*

Moderna (50%), Pfizer (12%), Trunk, extremities, face
Johnson and Johnson
(25%)

Grouped vesicles on an
erythematous base not
crossing the midline

All with viral cytopathic
changes present.
Involvement of the hair
follicle in 2 of 4 cases

31-72

Moderna (25%), Pfizer (75%) Trunk, extremities

No clinical images

Lichenoid interface
dermatitis; dermal
eosinophils may be
present

22-60

Moderna (33%), Pfizer (67%) Fingers, toes

Pink to violaceous papules
of the toes? fingers too?
Maybe just say
toes [ fingers or digits?

Perivascular lymphocytic
infiltrate with papillary
dermal edema and
interface changes

47-68

Moderna (50%), Pfizer (50%) Trunk, extremities, face

Erythematous, wellcircumscribed papules
and plaques without
surface change lasting \
24 h

Dermal edema with sparse
perivascular lymphocytes,
neutrophils and
eosinophils

68-93

Moderna (50%), Pfizer (50%) Trunk, extremities, face

Bright red to violaceous
dermal papules and
plaques

Dense dermal neutrophilic
infiltrate with papillary
dermal edema;
leukocytoclasis and
secondary vasculitic
changes may be present

57-61

Moderna (50%), Pfizer (50%) Lower extremities

Deep red to maroon
palpable purpura

Epidermal infiltrate of
neutrophils and
extravasated erythrocytes
with perivascular
neutrophils and
leukocytoclasis

50-85

Moderna (100%)

No clinical images

Perivascular mixed infiltrate;
interface changes may be
present

Lichen planus-like (n = 4)

J AM ACAD DERMATOL

Pernio (n = 3)

Urticaria (n = 2)

Neutrophilic dermatosis (n = 2)

Leukocytoclastic vasculitis (n = 2)

Morbilliform (n = 2)
Trunk, extremities

Continued
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Herpes zoster (n = 4)

Vaccine brand (%)

Distribution

Morphology (based on clinical
photograph review)

Histopathology

Delayed large local reactions (n = 2)
27-35

Moderna (100%)

Vaccinated arm

Indurated, erythematous
plaque

Superficial perivascular and
perifollicular lymphocytic
infiltrate with rare
eosinophils and scattered
mast cells

27

Moderna (100%)

Hands, feet

Erythematous, edematous
hands and feet (with
burning sensation)

Superficial and deep
perivascular inflammation
and edema

Stevens-Johnson Syndrome

46

Moderna (100%)

All skin surfaces, oral and
genital mucosa

Erythema multiforme

42

Moderna (100%)

Arms, hands

Granuloma annulare

85

Pfizer (100%)

Trunk

Tattoo sarcoidal reaction

38

Moderna (100%)

Leg

New onset psoriasis

67

Moderna (100%)

Trunk, extremities, head,
neck, face

Full-thickness epidermal
Atypical targetoid papules
necrosis
with duskiness, bullae,
and epidermal necrosis in
the center; hemorrhagic
crusting on the vermillion
lips; lesions involved
palms and soles
Erythematous, targetoid
Spongiotic and vacuolar
papules and plaques
interface dermatitis
No clinical images
Interstitial granulomatous
reaction
No clinical images
Tattoo with suppurativa
granulomatous
inflammation
Epidermal acanthosis,
Well demarcated
confluent parakeratosis
erythematous papules
with trapped clusters of
and plaques with
neutrophils, and focal
overlying silvery scale
spongiform pustule
formation. Diminished
thickness of granular layer

Erythromelalgia (n = 1)

Other (n = 5)

n 2021

BMZ, Basement membrane zone; BP, blood pressure; DIF, direct immunofluorescence; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; V-Repp, vaccine-related eruptions of
papules and plaques.
*These data from 58 biopsy reports represent a subset of the overall 803 cases in the registry, where biopsy was performed and the report was available for review. For clinical photos of these
reactions see Supplemental Fig 1.
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Fig 1. Spectrum of V-REPP following COVID-19 vaccination by degree of spongiosis and
interface changes present on histopathology. V-REPP, Vaccine-related eruption of papules and
plaques.

DISCUSSION
In this registry-based study, we grouped 58 biopsy
reports and clinical photographs of COVID-19 vaccine reactions into 13 patterns, with the most
common categories including V-REPP, bullous
pemphigoid-like, dermal hypersensitivity reactions,
herpes zoster, lichen planus-like, and pernio. The
relative frequency of these biopsy-proven categories
differs from the overall 803 dermatologic vaccine
reactions in the registry, possibly because providers
were less likely to biopsy common and welldescribed vaccine side effects, such as local injection
site reactions, delayed large local reactions, morbilliform eruptions, and urticaria. For example, for
delayed large local reactions occurring 4 days or
more after vaccination, there were 301 total reports
in the registry but just 2 were biopsied.
The most commonly biopsied reactions in the
registry were what we describe here as V-REPP
(Fig 1). The histopathologic spectrum of V-REPP all
showed some degree of spongiosis, ranging from
significant spongiosis with intraepidermal vesicle

formation (robust V-REPP), to pityriasis rosea-like
changes (moderate V-REPP), to minimal spongiosis
(mild V-REPP). One previously reported case of
pityriasis rosea-like eruption following a second
dose of the Pfizer vaccine similarly showed spongiosis with interface changes.8 Pityriasis rosea-like
eruptions have previously been described after
vaccination for smallpox, tuberculosis, polio, influenza, papillomaviruses, diphtheria, tetanus, hepatitis
B, pneumococcus, and yellow fever.9 Unlike classic
pityriasis rosea, pityriasis rosea-like reactions
following vaccination or medications may lack herald
patches and may feature a more diffuse papulosquamous exanthem, similar to what we observed in the
registry.9 Although the more robust papulovesicular
spectrum of V-REPP can clinically mimic an id reaction, there are several key distinctions. An id reaction
or autoeczematization, is generally a dermatitis
distant to an initial site of inflammation or infection;
it is not usually seen after vaccination, and would not
typically have the same spectrum of clinical and
pathologic changes.10
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The mechanism of V-REPP after COVID-19 vaccination is unknown, but the delayed occurrence of
these reactions suggests 2 potential mechanisms: (1)
delayed hypersensitivity response to vaccination; or
(2) T-cell-mediated skin reaction due to molecular
mimicry with a viral epitope. In fact, infection with
SARS-CoV-2 itself has been associated with pityriasis
rosea-like eruptions.11 Histopathology of pityriasis
rosea-like eruptions following SARS-CoV-2 infection
have similarly been reported to demonstrate spongiosis and a superficial perivascular lymphocytic
infiltrate.12 However, robust V-REPP, in which papulovesicles may be observed due to exuberant
spongiosis, appear to be different from other vesicular eruptions caused by true SARS-CoV-2 infection.
Vesicular eruptions by SARS-CoV-2 infection show
vacuolar degeneration on biopsy and have been
proposed to relate to direct cytotoxic effects of the
virus.13,14 Lesional biopsy demonstrated interface
changes, with parakeratosis and scattered dyskeratotic keratinocytes.
Histopathologic features of the more-common reaction patterns to Moderna and Pfizer vaccines have
been previously described in the literature. Similar to
our findings, histopathology of delayed large local
reactions showed perivascular lymphocytic infiltrates
with eosinophils and mast cells, consistent with a
delayed T-cell-mediated hypersensitivity reaction.15-17
Morbilliform eruptions after vaccination similarly
demonstrated perivascular lymphocytic inflammation.18 Additionally, some cutaneous vaccine
reactions, such as pernio/chilblains, had similar
morphology and histopathology to pernio described
in association with SARS-CoV-2 infection.11,19-21
Biopsy reports of additional dermatologic morphologies were also reported in the registry, such as
lichen planus, neutrophilic dermatoses, and psoriasis (Supplemental Fig 1). COVID-19 vaccines can
elicit strong T- and B-cell responses against SARSCoV-2. Their role and the mechanism by which they
might elicit off-target immune-stimulatory effects,
including provoking T-cell dependent disorders,
requires further study.22,23 We also observed other
immune-mediated dermatologic disorders, such as
bullous pemphigoid and leukocytoclastic vasculitis,
potentially driven by off-target immune activation
following COVID-19 vaccination.24 These shifts in
the immune response after vaccination may also be
associated with reactivation of other viruses; eg, 4
cases of confirmed herpes zoster with viral cytopathic changes observed in the registry.25,26
Although these cutaneous reactions may lead to
hesitation in receiving future vaccine doses, it is
important for patients and providers alike to recognize that in the cases of 2-dose vaccines, most

n 2021

eruptions, across a broad range of different reaction
patterns, did not lead to anaphylaxis or severe
adverse events with the second dose. It is important
to distinguish cutaneous reactions that can be
managed after a second dose (the majority of cases)
versus the rare reactions that represent absolute
contraindications.2,27 We did receive 1 report of
biopsy confirmed Stevens-Johnson syndrome
following vaccination, which represents an absolute
contraindication to second-dose vaccination.28
Our observational registry-based study has multiple limitations. Our overall registry case numbers
may not be representative of the true incidence or
prevalence of vaccine-associated cutaneous reactions, as providers may be more likely to submit
more-severe or uncommon cases to the registry.
Additionally, biopsy reports may be less representative of cutaneous vaccine reactions overall, given
provider predilection to reserve biopsies for unusual
and/or previously undescribed conditions, rather
than taking biopsies of more-common or easily
recognized conditions. This study is also limited in
generalizability, because patients in the registry were
predominantly from the United States where vaccine
roll out has been greatest for mRNA-based vaccines.
Additionally, this study relied on the text entered
from biopsy reports and clinical photographs, which
may oversimplify the interpretation of histopathologic and in-person evaluations. Another limitation is
that the V-REPP classification was not part of the
original registry entry choices, because this classification was developed during data analysis. These
cases were reclassified after review of photographs
and pathology reports by the authors of the study.
In conclusion, this case series demonstrated the
clinical and histopathologic characteristics of multiple dermatologic conditions after COVID-19 vaccination. We hope these data will aid physicians and
other providers in the diagnosis of dermatologic
conditions associated with the COVID-19 vaccine,
which will likely be encountered more frequently as
vaccine distribution expands globally.
We acknowledge the following individuals for
providing clinical and histology photographs and/or
clinical discussion of cases: Jayne Bird, Shannon Foster,
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